According to a research report published by J.P. Morgan Chase, Pharmacom Kangde's third-quarter revenue rose 38% year on year to 16.64 billion yuan, adjusted net profit rose 61% year on year to 6.81 billion yuan, and revenue from continuing operations increased 43.5% year on year, supporting another increase in the guidelines for the full year of this year. The bank also said that as the project progresses to late development and commercial production, it is believed that Pharmacovigant's revenue visibility will improve, and strong orders will also support next year's growth. AI drug discovery customers will bring additional laboratory demand, and production capacity expansion should support delivery. The bank believes that the current geopolitical risk has been reduced. It raised the target price of Yao Ming Kangde A shares from 200 yuan to 210 yuan, and the target price of H shares from HK$222 to HK$233. The rating is also “increased”, and it is still the preferred stock for CXO in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.